Latest:
Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer
Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jun Ma, MD
Latest:
Dr Ma on Sintilimab Plus Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Jun Ma, MD, discusses findings from the phase 3 CONTINUUM trial of sintilimab in combination with induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Vanda Salutari, MD
Vanda Salutari, MD, is an oncologist in the Department of Health of Woman and Child at the Catholic University of Sacred Heart, in Rome, Italy.
Latest:
Dr Salutari on the Rationale for Evaluating Relacorilant Plus Nab-Paclitaxel in PARP Inhibitor–Treated PROC
Vanda Salutari, MD, discusses the rationale for examining relacorilant plus nab-paclitaxel in PARP inhibitor–treated platinum-resistant ovarian cancer.
Jason Ye, MD
Jason Ye, MD, is the director of Clinical Operations of Radiation Oncology at University of Southern California (USC) Norris Comprehensive Cancer Hospital and associate professor of Clinical Radiation at Keck School of Medicine of USC.
Latest:
Coordinated Care in Breast Oncology: Encouraging Participation in Clinical Trials
Experts reflect on the power of clinical trial participation, multidisciplinary collaboration, and innovation to personalize care.
Mark Faries, MD
Mark Faries, MD, is a surgical oncologist at Cedars‑Sinai and The Angeles Clinic and Research Institute. He also serves as associate director of Surgical Oncology Experimental Therapeutics in the Cedars Sinai Department of Surgery, and is head of surgical oncology at Cedars-Sinai Medical Center.
Latest:
Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma
Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.